Is Novo Nordisk (NVO) Still a Buy in 2026? My Deep Dive into the Giant Curing Obesity
In 2026, Novo Nordisk (NVO) remains the undisputed leader in the GLP-1 market, bolstered by the record-breaking launch of its oral obesity pill. With a projected revenue CAGR of 11.41% and EPS growth of 13.93% through 2028, the company’s fundamentals are unmatched. Currently trading at a P/E ratio below 17—well under its 5-year median of […]






